Mumbai, Naples, May 15, 2025: Global pharma major Lupin Limited (Lupin) announced the appointment of Punita Lal as an Additional Director (Non-Executive, Independent) to its Board of Directors.

Punita has a distinguished career spanning over 35 years in strategy, marketing, and leadership across Asia, encompassing various geographies and industries. She has held senior positions at Coca-Cola in China and PepsiCo in India. She served as Managing Director & CEO of NourishCo, a joint venture between Tata Global Beverages and PepsiCo.

Following her executive tenure, Punita focused on consulting for SMEs, playing a significant role in fostering innovation. She is also a qualified leadership coach.

Punita has served on the boards of DBS Bank, Carlsberg A.S., Cipla, CEAT, and Entertainment Networks India. She has been recognized among India’s top 20 businesswomen by Business Today in 2006, and Corporate Woman of the Year by FICCI Women’s Organisation in 2009.

Punita’s academic credentials include a Bachelor of Arts (Honors) in Economics from St. Stephen’s College, Delhi, and an MBA from the Indian Institute of Management, Kolkata.

Manju D Gupta, Chairman, Lupin said, “We are delighted to welcome Punita to our board.  Her vast experience and expertise will be instrumental in guiding Lupin’s strategic initiatives and strengthening our position in the global pharmaceutical industry.”

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn  https://www.linkedin.com/company/lupin

For further information or queries please contact:

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com